DermatologyTimes - Dermatologic News and research spanning clinical, cosmetic specialties

ADVERTISEMENT

Previous StoryPlay / PauseNext Story

ADVERTISEMENT

Web Exclusive
Surviving melanoma: California woman marks five-year milestone with 76-mile trek
Napa, Calif. — Stage 4 melanoma survivor Kari Worth, 41, marked her five-year triumph over the disease with a five-day, 76-mile walk, ending with a trip across San Francisco’s Golden Gate Bridge to deliver a bottle of champagne to her oncologist.
In the Know

Given the vast amount of misinformation presented in the consumer media regarding cosmetic treatments, In The Know presents patients with information grounded in medicine and coming from the real experts. We talk with dermatologists and cosmetic surgeons on topics ranging from rosacea and acne, to fillers, lasers and facelifts. We hope the topics educate patients, inspire them to ask questions, and maybe even spur them to try a procedure.
To read our content, click here.

Beauty for a Lifetime
Research Briefs
MacroChem announces phase 2 data for EcoNail in treatment of onychomychosis
Jul 24, 2008
New York — MacroChem Corporation announces results of a phase 2 clinical trial of EcoNail,a topical antifungal for the treatment of onychomychosis, according to Earthtimes.org.
Melanoma rates rise in younger women
Jul 14, 2008
National report — The rate of melanoma cases in younger women has increased 50 percent since 1980, but did not increase in younger men, according to a study published in the Journal of Investigative Dermatology.
UV light therapy as beneficial for darker skin as lighter skin
Jul 9, 2008
Dallas — An analysis of more than 100 patients shows that darker-skinned patients benefit from light therapy to treat morphea and related diseases as much as lighter-skinned patients, according to ScienceDaily.
Etanercept demonstrates therapeutic effect on keloids
Jul 8, 2008
National report — A study shows that intralesional etanercept may provide an effective treatment for keloids, according to TherapeuticsDaily.
 More Articles
Industry News
NovaBay anounces details of dermatology program
Jul 21, 2008
Emeryville, Calif. — NovaBay Parmaceuticals announces it has successfully developed several formulations of Agonocide compounds for use in dermatology.
Galderma approved for Differin(R) Gel 0.1 percent in Japan
Jul 17, 2008
Lausanne, Switzerland — Galderma Pharma S.A. announced that Japan’s Health Labor and Welfare has approved Differin(R) Gel 0.1 percent (adapalene).
York Pharma raises £28 million to fund acquisitions
Jul 16, 2008
Milton Keynes, England — York Pharma has raised £28 million to fund a multi-million pound acquisition of Flammazine and Flammacerium from Solvay, according to BusinessWeekly.co.uk.
Dermatology Foundation seeks award nominees
Jul 11, 2008
Evanston, Ill. —The Dermatology Foundation is accepting nominations for the 2008 Clark W. Finnerud and 2008 Practitioner of the Year awards.
 More Articles
Special Report
Special Report

In this month’s Special Report, Dermatology Times looks at the the unique concerns of ethnic patients, including the skin conditions and cultural issues dermatologists should consider when treating blacks, Hispanics and Asian Americans. Blacks, for instance, often are diagnosed with melanoma at a later stage than are Caucasians.
To read our content, click here.

News
Brain drain: Dermatologists shunning, leaving academia
While schools known for academic dermatology produce and retain a relatively high proportion of academic dermatologists, the career path on the whole suffers from low interest among recent graduates — and high attrition rates over time, experts say.
Healthcare reform: Pollsters say Americans want change — but worry about the costs
The number of Americans who want "radical change" in the U.S. healthcare system has reached 36 percent, focusing intense national attention on the issue, says Republican pollster Bill McInturff, who has tracked the question since 1992.
FDA reviews tumor necrosis factor blockers: Scrutiny may worry some patients, derms say
The ongoing Food and Drug Administration (FDA) review of TNF-blocking biologic drugs is unlikely to have much impact on dermatologists' use of these drugs, physicians say.

ADVERTISEMENT

Dermatology Times issue
Stay connected to Dermatology Times
Receive new issue alerts, technology bulletins, and conference updates!

Help icon

Win a $100 gift card!

It’s easy — just complete our readership survey and be entered into a drawing to win one of five $100 gift cards!

If you’re a subscriber, we’ve already e-mailed the survey to you. Read our June print issue, then fill out the survey — it takes just a few minutes — and return it to us.

We value your feedback!

Tuberculosis Screenings Urged for Psoriasis Patients
New Laser Technique May Reduce Acne Scars
MacroChem announces phase 2 data for EcoNail in treatment of onychomychosis
Strong Arguments For and Against Sun's Role in Melanoma
'Tier 4' Drugs Raise Questions About Affordability
4th Annual Dermatology Nurses' Association Summer Meeting
August 02 - August 03
Bio-Therapeutic Bio-Dermatology Curriculum
August 11
Bio-Therapeutic Bio-Ultimate Platinum Curriculum
August 12
Bio-Therapeutic Bio-Brasion Curriculum
August 13
Bio-Therapeutic Bio-Oxygen Curriculum
August 14

Modern Medicine logoDermatology Times archives are now available on ModernMedicine.com, a new online resource designed to meet the evolving needs of physicians.
Register now (it's free and quick) or Find out more.

Keep visiting DermatologyTimes.com for fresh content, news, opinions, editor's blogs and more.

Click here